[Tab 1: Clinical Protocol & Regulatory Guidelines] BioVax Phase III Clinical Trial Operati… — GMAT

[Tab 1: Clinical Protocol & Regulatory Guidelines]
BioVax Phase III Clinical Trial Operations Policy (2026 Revision):
- Cohort Balance Rule: To ensure demographic representation, no single age group ( $<50$ years vs. $\ge 50$ years) may exceed $60\%$ of total enrolled participants at any trial site during a given quarter.
- Mandatory Audit Freeze: If a trial site experiences a quarterly participant dropout rate exceeding $15\%$ AND fails the Cohort Balance Rule in the same quarter, a mandatory 30-day participant enrollment freeze takes effect on the first day of the subsequent quarter.
- Waiver Exception Policy: A mandatory enrollment freeze is waived ONLY IF the site receives written approval from the Lead Investigator prior to the start of the subsequent quarter AND achieves an overall quarterly Patient Satisfaction Score of at least $4.2$ out of $5.0$ .

[Tab 2: Q3 Site Performance Audit Data]

Site ID	Location	Total Enrolled (Q3)	Enrolled Age <50	Enrolled Age ≥50	Q3 Dropouts	Patient Satisfaction Score	Written Waiver Date
Site 101	Boston	120	78	42	20	4.4	Sept 28
Site 102	Chicago	150	93	57	24	4.1	Sept 30
Site 103	Atlanta	100	62	38	17	4.5	None
Site 104	Denver	200	110	90	28	4.0	None

[Tab 3: Executive Operations Memorandum]
To: Regional Clinical Operations Monitors
From: Dr. E. Vance, Clinical Trial Director
Date: October 2, 2026
Subject: Q4 Enrollment Readiness & Freeze Enforcement
Final Q3 data reconciliation is complete. All mandatory 30-day enrollment freezes triggered by Q3 audit failures take effect October 1. Note that while Site 102 submitted a written waiver from the Lead Investigator dated September 30, regional monitors must strictly verify that all protocol prerequisites specified in the Clinical Protocol are satisfied before validating any waiver.

Based on the information provided across the three tabs, evaluate the following statement:
Site 102 was required to undergo a mandatory 30-day enrollment freeze starting October 1.

Cevap: Cevap

Cevap

The statement is True. Site 102 met both failure triggers for a mandatory audit freeze and failed to satisfy the satisfaction score threshold required for a valid waiver exemption.

The correct evaluation shows that Site 102 triggered a mandatory freeze by exceeding both the 60% demographic threshold (achieving 62%) and the 15% dropout limit (achieving 16%). Furthermore, its waiver was invalid because its Patient Satisfaction Score of 4.1 failed the strict 4.2 minimum threshold mandated by protocol.

Adım Adım Çözüm

Calculate the Q3 demographic proportion and dropout rate for Site 102 using Tab 2 data.

Age <50 proportion =

\frac{93}{150} = 62\%

. Dropout rate =

\frac{24}{150} = 16\%

Determine if Site 102 triggered the Mandatory Audit Freeze criteria specified in Tab 1.

Compare Site 102's calculated metrics against Tab 1 Mandatory Audit Freeze rules.

Both conditions are met:

62\% > 60\%

(Cohort Balance failure) and

16\% > 15\%

(Dropout threshold exceeded). A freeze was triggered.

Verify if an enrollment freeze was required prior to waiver considerations.

Evaluate Site 102's waiver eligibility against both criteria in Tab 1.

Written approval date (Sept 30) was before Oct 1 (Met), but Patient Satisfaction Score (

4.1

) was below the required

4.2

minimum (Failed).

Check if the written waiver granted to Site 102 effectively exempted it from the freeze.

Synthesize results with Tab 3 guidelines to form final determination.

Because the satisfaction score requirement was not met, the waiver is invalid under Tab 3 directives, confirming the statement as True.

Ensure all policy constraints across text and tabular sources are reconciled.

Anahtar Kavram

Multi-Source Policy Exception Synthesis

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru